

KAISER PERMANENTE®

# **Pre-Exposure Prophylaxis (PrEP) Educational Intervention in Primary Care**

Harold Cruz Sarmiento, DNP(c), MSN, AGPCNP-BC<sup>1,2</sup> Wei-Ti Chen, RN, CNM, PhD, FAAN<sup>1,</sup> Mary Ann Lewis, DrPH, RN, FAAN,<sup>1</sup> Colleen Keenan, PhD, RNC<sup>1;</sup> Elizabeth Thomas PhD, ANP-BC, COHNS-FAAOHN<sup>1</sup> <sup>1</sup>UCLA School of Nursing, Los Angeles, CA<sup>2</sup>Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA

### Introduction

- Around 1.2 million people in the United States (U.S.) are currently • infected with HIV (CDC, 2021).
- Pre-Exposure Prophylaxis (PrEP) is safe and highly effective in • preventing HIV infection.
- However, PrEP remains underutilized among primary care providers (PCPs) due to lack of knowledge and education on PrEP (CDC, 2021).
- PCPs at Kaiser Permanente (KP) Los Angeles Medical Center do not  $\bullet$ prescribe PrEP to at-risk patients and refer them to infectious disease providers.

### Purpose

The proposed PrEP educational intervention (PrEP-EI) will provide PCP's in-depth knowledge on prescribing PrEP to help them adapt and implement PrEP in their practice.

# Methods

#### **Design**:

- Pre- and post-test design was used to assess the participant's knowledge level of PrEP.
- 35 PCPs attended the PrEP-EI and were given pre- and post-tests.

### **Data Collection:**

- PCPs were given a survey link to Microsoft Form<sup>®</sup> to answer 5 PrEP knowledge-based questions pre-and post- PrEP-EI.
- The number of PrEP medications (Truvada<sup>®</sup> and Descovy<sup>®</sup> or the generic version emtricitabine and tenofovir disoproxil fumarate) prescription at the pharmacy was documented at baseline and 2 months after the PrEP-EI.
- PCP's demographics were obtained from pre-implementation survey.

### **Data Analysis:**

Paired Samples *t*-Test was used, there must be a *p*-value of <0.05 to reject the null hypothesis.

### Results

#### Table 1. PCP Characteristics (n = 27)

Characteristics	MD/DO	NP/PA	Total
<b>Age</b> [mean] Range	45(28-65)		MD/DO = 35 NP/PA = 0
Gender			
Male	18		51%
Female	17		49%
Ethnicity			
White	10		29%
Black	1		3%
Hispanic	4		11%
Asian	18		51%
Mixed/Others	2		6%
Specialty			
Internal	27		93%
Medicine			
Family	8		7%
Medicine			
Years in			
Practice			
< 5 years	14		40%
6-15 years	11		31%
> 15 years	10		29%

#### Table 2. Knowledge Level of PrEP

	Pre-test	Post-test
PrEP Knowledge Level	60%	90.86%

Before the PrEP-EI, participants had a knowledge score of 60%. After the PrEP-EI, knowledge score increased to 90.86%.



### Table 3. Number of PrEP Medication Prescriptions

	Baseline	2 months after PrEP-EI
Number of PrEP Medications	12	76

The number of PrEP medications prescribed by PCPs increased from 12 to 76 in 2 months.

## Conclusions

PrEP-EI has been shown to increase PrEP knowledge among PCPs.

• This finding supports the importance of PrEP-El among PCPs to prescribe PrEP.

PCPs are more likely to adapt and implement PrEP in their clinical practice when trained with the necessary knowledge and skills.

# **Clinical Implications**

PrEP is a cost-effective and safe way to prevent HIV infection. Establishing PCP's knowledge and competence of PrEP is critical to facilitating their adaption of PrEP in clinical practice. PrEP is a prevention intervention and is vital in ending the HIV epidemic in the U.S.

> Ending The HIV **Epidemic**

